{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:12:46Z","timestamp":1780567966349,"version":"3.54.1"},"reference-count":53,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>T-lineage acute lymphoblastic leukemia (T-ALL) is curable for most children and adolescent and young adult patients with contemporary frontline chemotherapy regimens. During the past decade, improved survival rates have resulted from the optimization of frontline chemotherapy regimens, the use of minimal residual disease (MRD) assessment for evaluating a patient's risk for relapse, and the intensification of treatment based on the persistence of MRD. Optimization of initial therapy is critical because relapsed T-ALL after initial intensive chemotherapy is incurable for most adult patients. Current T-ALL salvage chemotherapy regimens are minimally effective, and unlike in B-cell ALL, there are no approved antibody therapies or chimeric antigen receptor T-cell therapies for relapsed disease. Immunotherapy and small-molecule inhibitors are beginning to be tested in relapsed T-ALL and have the potential to advance the treatment. Until effective salvage strategies are discovered, however, intensive frontline therapy is required for cure. In this article I review the current frontline chemotherapy regimens for adult patients with T-ALL, summarize the novel targeted and immune therapeutics currently in early-phase clinical trials, and outline how these therapies are helping to define an optimal approach for T-ALL.<\/jats:p>","DOI":"10.1182\/hematology.2022000337c","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:08:50Z","timestamp":1670602130000},"page":"197-205","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Optimal approach to T-cell ALL"],"prefix":"10.1182","volume":"2022","author":[{"given":"Kristen M.","family":"O'Dwyer","sequence":"first","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"2022120916075387600_hem2022000337CC1","author":"American Cancer Society","year":"2022"},{"issue":"11","key":"2022120916075387600_hem2022000337CC2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2012.080432","article-title":"Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts","volume":"98","author":"Chiaretti","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"2022120916075387600_hem2022000337CC3","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/10428194.2018.1522442","article-title":"Incidence and survival of T-cell acute lymphoblastic leukemia in the United States","volume":"60","author":"Guru Murthy","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"2022120916075387600_hem2022000337CC4","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2022120916075387600_hem2022000337CC5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41375-019-0598-2","article-title":"T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol","volume":"34","author":"Quist-Paulsen","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"2022120916075387600_hem2022000337CC6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","article-title":"The genetics and molecular biology of T-ALL","volume":"129","author":"Girardi","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2022120916075387600_hem2022000337CC7","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2012","journal-title":"J Clin Invest"},{"issue":"28","key":"2022120916075387600_hem2022000337CC8","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"2022120916075387600_hem2022000337CC9","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2022120916075387600_hem2022000337CC10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2022120916075387600_hem2022000337CC11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"2022120916075387600_hem2022000337CC12","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"2022120916075387600_hem2022000337CC13","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2022120916075387600_hem2022000337CC14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13046-022-02421-2","article-title":"Expanding anti-CD38 immunotherapy for lymphoid malignancies","volume":"41","author":"Wang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"30","key":"2022120916075387600_hem2022000337CC15","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"2022120916075387600_hem2022000337CC16","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"2022120916075387600_hem2022000337CC17","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2022120916075387600_hem2022000337CC18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2022120916075387600_hem2022000337CC19","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"2022120916075387600_hem2022000337CC20","doi-asserted-by":"crossref","unstructured":"Wang\n              X\n            , LiS, GaoL, et al.\n          Clinical safety and efficacy study of TruUCAR GC027: the first-in-human, universal CAR-T therapy for adult relapsed\/refractory T-cell `acute lymphoblastic leukemia. Paper presented at: 2020 American Association for Cancer Research Virtual Annual Meeting; 2020; virtual meeting; Abstract CT052.","DOI":"10.1158\/1538-7445.AM2020-CT052"},{"key":"2022120916075387600_hem2022000337CC21","unstructured":"Rodriguez\n              CO\n              Jr\n            , MitchellBS, AyresM, ErikssonS, GandhiV. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002;62(11):3100-3105.\u2002https:\/\/aacrjournals.org\/cancerres\/article\/62\/11\/3100\/508847\/Arabinosylguanine-Is-Phosphorylated-by-Both. Accessed 18October2022."},{"key":"2022120916075387600_hem2022000337CC22","unstructured":"Verhoef\n              V\n            , FridlandA. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res. 1985;45(8):3646-3650. https:\/\/aacrjournals.org\/cancerres\/article\/45\/8\/3646\/489921\/Metabolic-Basis-of-Arabinonucleoside-Selectivity. Accessed 18October2022."},{"issue":"4","key":"2022120916075387600_hem2022000337CC23","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood.V61.4.660.660","article-title":"Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells","volume":"61","author":"Cohen","year":"1983","journal-title":"Blood"},{"issue":"15","key":"2022120916075387600_hem2022000337CC24","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"2022120916075387600_hem2022000337CC25","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2022120916075387600_hem2022000337CC26","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","article-title":"High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation","volume":"118","author":"G\u00f6kbuget","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2022120916075387600_hem2022000337CC27","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ajh.25957","article-title":"Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study","volume":"95","author":"Candoni","year":"2020","journal-title":"Am J Hematol"},{"issue":"18","key":"2022120916075387600_hem2022000337CC28","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-06-0606","article-title":"Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia\/lymphoma","volume":"12","author":"Cohen","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2022120916075387600_hem2022000337CC29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ajh.26144","article-title":"Outcome of T-cell acute lymphoblastic leukemia\/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine","volume":"96","author":"Morita","year":"2021","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2022120916075387600_hem2022000337CC30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2021-152355","article-title":"First analysis of the UKALL14 randomized trial to determine whether the addition of nelarabine to standard chemotherapy improves event free survival in adults with T-cell acute lymphoblastic leukemia (CRUK\/09\/006P)","volume":"138","author":"Rowntree","year":"2021","journal-title":"Blood"},{"issue":"24","key":"2022120916075387600_hem2022000337CC31","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2022120916075387600_hem2022000337CC32","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"16","key":"2022120916075387600_hem2022000337CC33","article-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma: results from the phase 2 DELPHINUS study [abstract]","volume":"40","author":"Hogan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022120916075387600_hem2022000337CC34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"issue":"25","key":"2022120916075387600_hem2022000337CC35","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","article-title":"Targeting the B-cell lymphoma\/leukemia 2 family in cancer","volume":"30","author":"Davids","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2022120916075387600_hem2022000337CC36","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"9","key":"2022120916075387600_hem2022000337CC37","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"7","key":"2022120916075387600_hem2022000337CC38","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"2022120916075387600_hem2022000337CC39","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Del Gaizo Moore","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2022120916075387600_hem2022000337CC40","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"2022120916075387600_hem2022000337CC41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2005.10.018","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review","volume":"12","author":"Hahn","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2022120916075387600_hem2022000337CC42","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a Group for Research on Adult Acute Lymphoblastic Leukemia study","volume":"35","author":"Bond","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"2022120916075387600_hem2022000337CC43","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2022120916075387600_hem2022000337CC44","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.24285","article-title":"Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission","volume":"91","author":"Seftel","year":"2016","journal-title":"Am J Hematol"},{"issue":"7","key":"2022120916075387600_hem2022000337CC45","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41375-021-01213-5","article-title":"Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph- negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR","volume":"35","author":"Wieduwilt","year":"2021","journal-title":"Leukemia"},{"issue":"16","key":"2022120916075387600_hem2022000337CC46","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2022120916075387600_hem2022000337CC47","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","article-title":"Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial","volume":"32","author":"Ribera","year":"2014","journal-title":"J Clin Oncol"},{"issue":"14","key":"2022120916075387600_hem2022000337CC48","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2020007311","article-title":"Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia","volume":"137","author":"Ribera","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2022120916075387600_hem2022000337CC49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-020-00383-2","article-title":"Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10\/07","volume":"10","author":"Bassan","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"2022120916075387600_hem2022000337CC50","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2017.04.003","article-title":"Allogeneic hematopoietic cell transplantation for adult T cell acute lymphoblastic leukemia","volume":"23","author":"Hamilton","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2022120916075387600_hem2022000337CC51","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/bmt.2015.278","article-title":"Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"51","author":"Cahu","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2022120916075387600_hem2022000337CC52","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.bbmt.2012.07.011","article-title":"Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia","volume":"18","author":"Bakr","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2022120916075387600_hem2022000337CC53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bmt.2016.194","article-title":"Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes","volume":"52","author":"Brammer","year":"2017","journal-title":"Bone Marrow Transplant"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/197\/2020811\/197odwyer.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/197\/2020811\/197odwyer.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:09:17Z","timestamp":1670602157000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/197\/493485\/Optimal-approach-to-T-cell-ALL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000337c","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}